Brain+ A/S Announces Cognitive Stimulation Therapy Enhances the Effects of Alzheimer's Disease Medicine
medication today), as highlighted in five studies summarized by Orrell and colleagues (2017). This highlights the synergistic effect of CST with ACHEI medication for patients with Alzheimer's disease and represents a promising avenue for pharma partnerships on combining Brain+ CST products with Alzheimer's medications, both the classic ACHEI and the newer medicines being approved. CST positioned to become global standard of care: The 2nd Cochrane review is another major support of CST, following the recommendation in 2022, where CST was recommended for global implementation in the World Alzheimer's Report 2022 and was highlighted in the World Health Organization's major report on dementia research and care. Brain+ is uniquely positioned to benefit from this positive momentum for CST, as the pioneer of digital CST and working with the global Key Opinion Leaders. CST is
now used in 37 countries, and Brain+ has initially targeted Denmark (home market), Germany, the United Kingdom and the United States.